Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 AlectorREGENXBIOKrystal BiotechImmunovantOcugen
SymbolNASDAQ:ALECNASDAQ:RGNXNASDAQ:KRYSNASDAQ:IMVTNASDAQ:OCGN
Price Information
Current Price$18.45$34.25$79.37$16.02$7.45
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.31.61.51.81.1
Analysis Score3.53.43.54.51.4
Community Score2.42.72.53.73.4
Dividend Score0.00.00.00.00.0
Ownership Score0.81.71.70.80.0
Earnings & Valuation Score0.00.00.00.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$34.00$62.50$101.00$45.60$4.80
% Upside from Price Target84.28% upside82.48% upside27.25% upside184.64% upside-35.57% downside
Trade Information
Market Cap$1.44 billion$1.43 billion$1.73 billion$1.52 billion$1.22 billion
Beta1.081.281.2N/A3.56
Average Volume630,158451,016149,1071,415,88956,026,848
Sales & Book Value
Annual Revenue$21.22 million$35.23 millionN/AN/AN/A
Price / Sales69.2041.32N/AN/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$2.83 per share$12.23 per share$11.72 per share$1.45 per share$0.21 per share
Price / Book6.522.80N/AN/AN/A
Profitability
Net Income$-105,390,000.00$-94,730,000.00$-19,090,000.00$-66,390,000.00$-20,240,000.00
EPS($1.71)($3.26)($1.20)($1.54)($1.48)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-757.78%-63.13%N/AN/AN/A
Return on Equity (ROE)-53.86%-21.73%-10.72%-34.80%-47.72%
Return on Assets (ROA)-31.44%-18.74%-10.40%-32.38%-30.78%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/A0.13%
Current Ratio6.61%6.08%39.96%35.15%4.78%
Quick Ratio6.61%6.08%39.96%35.15%4.78%
Ownership Information
Institutional Ownership Percentage61.50%75.23%73.05%40.21%8.53%
Insider Ownership Percentage13.90%14.10%27.40%0.24%3.54%
Miscellaneous
Employees171257754216
Shares Outstanding79.58 million42.51 million22.20 million97.97 million188.09 million
Next Earnings Date5/12/2021 (Estimated)5/6/2021 (Estimated)5/3/2021 (Estimated)7/5/2021 (Estimated)5/14/2021 (Estimated)
OptionableNot OptionableOptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Ocugen Partner Reports Strong Phase 3 Results for Coronavirus Vaccine - Motley FoolOcugen Partner Reports Strong Phase 3 Results for Coronavirus Vaccine - Motley Fool
fool.com - April 22 at 9:25 AM
Why Ocugen Stock Surged Today - The Motley FoolWhy Ocugen Stock Surged Today - The Motley Fool
fool.com - April 22 at 9:25 AM
Ocugen Partner Reports Strong Phase 3 Results for Coronavirus VaccineOcugen Partner Reports Strong Phase 3 Results for Coronavirus Vaccine
finance.yahoo.com - April 22 at 9:25 AM
Ocugen Inc. (OCGN) stock gains in the pre-market trading session. Whats driving it higher? - Catching NewsOcugen Inc. (OCGN) stock gains in the pre-market trading session. What's driving it higher? - Catching News
catchingnews.com - April 22 at 12:08 AM
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Second Interim Results demonstrating 100% Protection against Severe Disease including Hospitalization - Yahoo FinanceOcugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Second Interim Results demonstrating 100% Protection against Severe Disease including Hospitalization - Yahoo Finance
finance.yahoo.com - April 22 at 12:08 AM
Ocugen, Inc. (NASDAQ:OCGN) Director Ramesh Kumar Sells 7,500 SharesOcugen, Inc. (NASDAQ:OCGN) Director Ramesh Kumar Sells 7,500 Shares
americanbankingnews.com - April 21 at 4:50 PM
Why Bionano Genomics, Ocugen Are Rallying Today - BenzingaWhy Bionano Genomics, Ocugen Are Rallying Today - Benzinga
benzinga.com - April 21 at 2:04 PM
Ocugen (NASDAQ:OCGN) Stock Price Up 14.3%Ocugen (NASDAQ:OCGN) Stock Price Up 14.3%
americanbankingnews.com - April 21 at 11:43 AM
Why Bionano Genomics, Ocugen Are Rallying TodayWhy Bionano Genomics, Ocugen Are Rallying Today
markets.businessinsider.com - April 21 at 9:29 AM
OCGN Stock: The Huge COVAXIN News Sending Ocugen Climbing TodayOCGN Stock: The Huge COVAXIN News Sending Ocugen Climbing Today
feedproxy.google.com - April 21 at 9:08 AM
Thinking about buying stock in Welbilt, Ocugen, Obseva, Ericsson, or Citius Pharmaceuticals? - Troy RecordThinking about buying stock in Welbilt, Ocugen, Obseva, Ericsson, or Citius Pharmaceuticals? - Troy Record
troyrecord.com - April 21 at 9:04 AM
Ocugens COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Second Interim Results demonstrating 100% Protection against Severe Disease including Hospitalization - GlobeNewswireOcugen's COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Second Interim Results demonstrating 100% Protection against Severe Disease including Hospitalization - GlobeNewswire
globenewswire.com - April 21 at 9:04 AM
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Second Interim Results demonstrating 100% Protection against Severe Disease including HospitalizationOcugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Second Interim Results demonstrating 100% Protection against Severe Disease including Hospitalization
finance.yahoo.com - April 21 at 9:04 AM
Bharat Biotech, government cash and partners in hand, aims for 700M COVID-19 shots per year - FiercePharmaBharat Biotech, government cash and partners in hand, aims for 700M COVID-19 shots per year - FiercePharma
fiercepharma.com - April 21 at 12:08 AM
Ocugens Partner Bharat Biotech Ramping Manufacturing To Produce 700M COVID-19 Vaccine Doses Annually - BenzingaOcugen's Partner Bharat Biotech Ramping Manufacturing To Produce 700M COVID-19 Vaccine Doses Annually - Benzinga
benzinga.com - April 21 at 12:08 AM
Ocugen Enters Oversold Territory (OCGN) - NasdaqOcugen Enters Oversold Territory (OCGN) - Nasdaq
nasdaq.com - April 20 at 2:08 PM
Ocugens Partner Bharat Biotech Ramping Manufacturing To Produce 700M COVID-19 Vaccine Doses Annually - Yahoo FinanceOcugen's Partner Bharat Biotech Ramping Manufacturing To Produce 700M COVID-19 Vaccine Doses Annually - Yahoo Finance
finance.yahoo.com - April 20 at 2:08 PM
Ocugens Outlook Is Still Very Bleak - Investorplace.comOcugen's Outlook Is Still Very Bleak - Investorplace.com
investorplace.com - April 20 at 2:08 PM
Ocugen’s Outlook Is Still Very BleakOcugen’s Outlook Is Still Very Bleak
feedproxy.google.com - April 20 at 1:02 PM
Ocugen (NASDAQ:OCGN) Shares Gap Up to $5.64Ocugen (NASDAQ:OCGN) Shares Gap Up to $5.64
americanbankingnews.com - April 20 at 11:40 AM
Reddit Traders Cant Get Enough of These 2 Resurgent Biotech StocksReddit Traders Can't Get Enough of These 2 Resurgent Biotech Stocks
finance.yahoo.com - April 20 at 9:07 AM
Analyzing BioCardia (NASDAQ:BCDA) and Ocugen (NASDAQ:OCGN)Analyzing BioCardia (NASDAQ:BCDA) and Ocugen (NASDAQ:OCGN)
americanbankingnews.com - April 19 at 6:22 PM
Is Ocugen (OCGN) a Better Biotech Stock Top Buy Near $5 This Week? – Own Snap - Own SnapIs Ocugen (OCGN) a Better Biotech Stock Top Buy Near $5 This Week? – Own Snap - Own Snap
ownsnap.com - April 19 at 2:12 PM
Ocugen (NASDAQ:OCGN) Shares Gap Down to $5.78Ocugen (NASDAQ:OCGN) Shares Gap Down to $5.78
americanbankingnews.com - April 19 at 11:40 AM
Ocugen, Inc (OCGN) Stock Price Continue to Stumble Amidst IP Uncertainty - Knox DailyOcugen, Inc (OCGN) Stock Price Continue to Stumble Amidst IP Uncertainty - Knox Daily
knoxdaily.com - April 19 at 9:11 AM
DateCompanyBrokerageAction
4/19/2021AlectorMorgan StanleyBoost Price Target
1/15/2021AlectorBank of AmericaInitiated Coverage
11/11/2020AlectorSmith Barney CitigroupLower Price Target
7/29/2020AlectorBarclaysLower Price Target
6/24/2020AlectorHC WainwrightInitiated Coverage
4/28/2020AlectorThe Goldman Sachs GroupInitiated Coverage
3/5/2020AlectorCitigroupInitiated Coverage
2/18/2020AlectorStifel NicolausInitiated Coverage
12/16/2019AlectorCowenReiterated Rating
11/27/2019AlectorBTIG ResearchInitiated Coverage
3/4/2019AlectorSVB LeerinkInitiated Coverage
1/20/2021REGENXBIORoyal Bank of CanadaBoost Price Target
1/6/2021REGENXBIORaymond JamesUpgrade
12/15/2020REGENXBIOUBS GroupInitiated Coverage
8/14/2020REGENXBIOChardan CapitalReiterated Rating
11/11/2019REGENXBIOEvercore ISIReiterated Rating
2/9/2021Krystal BiotechJonestradingInitiated Coverage
11/11/2020Krystal BiotechB. RileyReiterated Rating
5/4/2020Krystal BiotechWilliam BlairReiterated Rating
9/26/2019Krystal BiotechGuggenheimSet Price Target
2/2/2021ImmunovantCredit Suisse GroupDowngrade
11/13/2020ImmunovantTruistBoost Price Target
11/13/2020ImmunovantRobert W. BairdBoost Price Target
10/6/2020ImmunovantLifesci CapitalReiterated Rating
10/2/2020ImmunovantCSFBInitiated Coverage
3/4/2021OcugenRoth CapitalBoost Price Target
2/3/2021OcugenCantor FitzgeraldBoost Price Target
(Data available from 4/22/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.